PTC Therapeutics Inc. Common Stock (PTCT)

FairStock Score: 78/100 — HIGH CONVICTION

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I look for durable cash generation bought at a discount. PTC Therapeutics is a rare-disease biotech, not a classic Buffett franchise. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported revenue of $360.5 million, net income of $83.5 million, and diluted EPS of $0.92. For FY2025, the period ended 2025-12-31, revenue was $1.7 billion, net income $682.6 million, and diluted EPS $7.78, compared with FY2024 revenue of $806.8 million, net loss of $363.3 million, and diluted EPS of -$4.73. That is a dramatic swing, and FairStock calls it a TURNAROUND because it returned to profit after losses within the last three years. But the quality of that turnaround is not yet proven. Trailing free cash flow is -$332.6 million, with an FCF yield of -6.6% as FairStock calculates, and the Altman Z-score of 0.58 suggests financial fragility. ROCE is only 2.46%, and the Piotroski F-score of 7/9 is encouraging but not conclusive. At the $59.92 close on 2026-10-13, market cap is $5.0 billion. The P/E of -96.65 is not meaningful, while EV/EBITDA of 26.78 is rich if cash flow remains negative. Rare-disease medicines can have pricing power and limited competition, but regulatory and pipeline risks are real. The recent profit is welcome, yet I see no clear margin of safety until PTC produces sustained positive free cash flow.

In plain English: PTC Therapeutics makes medicines for rare diseases, including Duchenne muscular dystrophy and other serious disorders. The business looks mixed: it has recently made a profit and revenue has grown quickly, but it still uses more cash than it brings in and has a history of losses. At the $59.92 close on 2026-10-13, the price looks expensive compared with current profits and cash flow, even though the turnaround is promising.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer